Back to search results

StrataCTX® for Skin Reactions in CTCL and Chemotherapy

This study is testing if StrataCTX® gel can help reduce the need for topical steroids in people with skin reactions. This includes individuals with cutaneous T-cell lymphoma (CTCL) who experience contact dermatitis from mechlorethamine gel, or have severe itching, or rely heavily on steroids. It also includes people receiving chemotherapy or immunotherapy for other conditions who have skin reactions. The study aims to see if StrataCTX® can be a better option than standard topical steroids. Success will be measured by changes in your itching levels over three months.

Study design
This is an interventional study planning to enroll 70 participants. The phase of the study is not specified.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your itching levels will be measured from the start of the study through 3 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04087629

StrataCTX® as a Steroid Sparing Device

Recruiting
NAAges 18+InterventionalSupportive care
Columbia University
~70 participants
Updated 2026-09-11 on ClinicalTrials.gov
What's tested:StrataCTX® gel

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in Pruritus Visual Analogue Scale (VAS) Score
Measured over Screening through 3 months

Conditions

CTCL

Explore related trials

Hematologic NeoplasmPrimary Cutaneous T-Cell Non-Hodgkin LymphomaSolid Neoplasm

NCT04087629

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Columbia University Irving Medical Center

    New York, New Yorkstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Larisa J. Geskin, MD · PRINCIPAL_INVESTIGATOR · Columbia University

Who to contact

Larisa Geskin, MD
[email protected]
212-305-5293
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥ 18 years
Ability to sign informed consent document
Patient with a diagnosis of CTCL who have contact dermatitis to topical mechlorethamine gel
Patients with a diagnosis of CTCL who have intractable pruritis
Patients with a diagnosis of CTCL who rely heavily on topical steroids for symptomatic relief
Patients on chemo/immunotherapy with drug induced rash

Exclusion

Patients currently undergoing radiotherapy
Patients currently receiving oral steroids
Patients who are unable to apply topical medications

What this trial measures

  • Change in Pruritus Visual Analogue Scale (VAS) ScoreScreening through 3 months

    The primary objective of this study is to determine whether StrataCTX® gel is effective as a supportive therapy for cutaneous reactions treated with topical steroids as the standard of care. This objective will be measured by the Pruritus Visual Analogue Scale, which measures self-reported itching on a scale of 0 (no itching) (better outcome) to 10 (worst imaginable itch).